middle.news
Clarity Pharmaceuticals Showcases Superior Prostate Cancer Imaging and Therapy Data at EANM 2026
9:56am on Monday 29th of June, 2026 AEST
•
Healthcare
Read Story
Clarity Pharmaceuticals Showcases Superior Prostate Cancer Imaging and Therapy Data at EANM 2026
9:56am on Monday 29th of June, 2026 AEST
Key Points
64Cu-SAR-bisPSMA outperforms standard PSMA PET imaging in lesion detection
Next-day imaging significantly increases lesion visibility and alters patient management
67Cu-SAR-bisPSMA therapy leads to undetectable disease in metastatic prostate cancer cases
Data supports ongoing Phase III trials and potential commercialisation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE